Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018
Friday, March 15, 2019 2:00 AM
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 15, 2019 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today published its audited Financial Results for 2018 and the company's 2018 Annual Report.
The Audited Financial Results for 2018 and the company's 2018 Annual Report are available on the investors section of the company' website.
- April 16, 2019 - Annual General Meeting
- May 9, 2019 - Interim Management Statement Q1 2019
- August 27, 2019 - Publication of Half-year Results 2019 (unaudited)
- October 31 - Interim Management Statement Q3 2019
About the DARPin® Difference
DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than five targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.
With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2, and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin ® is a registered trademark owned by Molecular Partners AG.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to www.molecularpartners.com.
For further details, please contact:
Dr. Patrick Amstutz, CEO
Tel: +41 (0) 44 755 77 00
Dr. Thomas Schneckenburger, IR & Media
Tel: +41 (0) 44 755 5728
Susan A. Noonan, IR USA
Tel: +1 212 966 3650
Lisa Raffensperger, International Media
Tel: +1 617-903-8783
*DARPin® is a registered trademark owned by Molecular Partners AG
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intention.
SOURCE: Molecular Partners AG